In summary, the introduction of disease-modifying anti-rheumatic drugs can control inflammation and exert beneficial effects on insulin resistance and insulin sensitivity in RA patients, potentially reducing the risk of developing T2D in non-diabetic individuals or aiding in the achievement of better glucose control in diabetics. This evidence concerns the gene INS and Insulin resistance.